Astra Zeneca's monoclonal antibodies
GPTKB entity
Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:accessories |
during pandemic
with other manufacturers |
| gptkbp:activities |
neutralizes virus
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:business_model |
adhered to in trials
|
| gptkbp:clinical_trial |
diverse demographics
multiple countries Phase 3 randomized controlled trials positive outcomes published in journals measured in trials multiple phases conducted |
| gptkbp:collaborated_with |
gptkb:University_of_Oxford
|
| gptkbp:collaborations |
various academic institutions
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:distribution |
coordinated with governments
|
| gptkbp:dosage_form |
based on weight
|
| gptkbp:economic_impact |
significant during COVID-19
|
| gptkbp:education |
important for understanding treatment
|
| gptkbp:feedback |
collected for improvement
|
| gptkbp:formulation |
liquid solution
|
| gptkbp:frequency |
single dose
|
| gptkbp:future_plans |
ongoing studies
|
| gptkbp:healthcare |
potentially transformative
critical in pandemic response improved for high-risk groups influenced by findings |
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca's monoclonal antibodies
|
| gptkbp:indication |
prevention of COVID-19
|
| gptkbp:innovation |
in antibody development
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
reduces hospitalization risk
|
| gptkbp:is_monitored_by |
required post-administration
|
| gptkbp:is_used_for |
treatment of COVID-19
|
| gptkbp:marketed_as |
gptkb:Evusheld
|
| gptkbp:partnerships |
with various organizations
|
| gptkbp:pharmacokinetics |
monitored in studies
|
| gptkbp:produced_by |
biotechnology methods
|
| gptkbp:provides_information_on |
updated regularly
recommended for certain patients |
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:receives_funding_from |
public and private sectors
|
| gptkbp:recruitment |
based on risk factors
|
| gptkbp:regulatory_compliance |
emergency use authorization
ensured throughout development |
| gptkbp:research_focus |
immunology
|
| gptkbp:safety_features |
generally well-tolerated
ongoing during trials |
| gptkbp:scholarships |
provided during treatment.
|
| gptkbp:side_effect |
allergic reactions
reported in trials |
| gptkbp:storage |
refrigerated
|
| gptkbp:student_enrollment |
specific criteria
|
| gptkbp:supply_chain |
global distribution
|
| gptkbp:target_audience |
high-risk individuals
|
| gptkbp:targets |
SARS-Co V-2 virus
|
| gptkbp:training |
necessary for administration
|
| gptkbp:treatment |
evaluated in studies
monitored long-term |